Nektar's cash surge to $953M de-risks financing, but Phase 3 proof still pending

What happened

Nektar Therapeutics reported third quarter 2026 cash and investments of $952.9 million, up from $245.8 million at December 31, 2025, a more than fivefold increase that signals the successful closure of its $300 million public offering and likely additional capital inflows. The company had previously guided that funding was a critical gating item for advancing rezpegaldesleukin into two FDA-aligned Phase 3 trials in atopic dermatitis, with a start window of Q2 2026. While the cash position now provides substantial runway for pivotal trial execution and manufacturing support, the earnings release did not explicitly confirm whether the Phase 3 trials initiated on schedule. Investors should note that the prior WAIT rating was contingent on both financing terms and observable proof of Phase 3 activation on ClinicalTrials.gov, and the latter remains unverified from this announcement. The strengthened balance sheet removes a major overhang, but the clinical execution milestone is still the key value driver.

Implication

The jump to $952.9 million in cash largely resolves the financing-related downside scenario that anchored the previous WAIT rating, as the company now has ample capital to fund Phase 3 trials and manufacturing needs without immediate dilution risk. However, the quarterly update did not provide clarity on whether the two registrational trials actually started in Q2 2026, leaving a critical operational checkpoint unanswered. Investors should monitor ClinicalTrials.gov for protocol postings and site activation consistent with the disclosed FDA alignment on dose and co-primary endpoints. A confirmed Phase 3 start would materially de-risk the story and could shift the rating toward a more constructive stance. Until then, the investment case remains contingent on execution rather than financial resources alone, and patience is warranted.

Thesis delta

The thesis shifts from a dual focus on financing terms and Phase 3 initiation to primarily waiting on Phase 3 initiation evidence, as the financing overhang appears resolved with the cash increase to $952.9 million. The WAIT rating still holds because the core value inflection—proof that pivotal trials are underway—has not been confirmed in this release. If the company subsequently discloses active Phase 3 enrollment, the rating would likely upgrade as the financing and operational risks both become manageable.